Facebook
Linkedin
Pinterest
Reddit
Twitter
Medical Devices
Biotechnology
Clinical Trials
Mergers & Acquisitions
Funding
FDA
Industry Expert Articles
Other News
Market Reports
Executives
Hospitals
Imaging
Ultrasound
Health
Articles
Search
CERo Therapeutics
CERo Therapeutics Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
CERo Therapeutics is continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA
June 6, 2024
Exit mobile version